Treatment with a Rho Kinase Inhibitor Improves Survival from Graft-Versus-Host Disease in Mice after MHC-Haploidentical Hematopoietic Cell Transplantation

Slides:

Advertisements

Similar presentations

Reduced Graft-versus-Host Disease in C3-Deficient Mice Is Associated with Decreased Donor Th1/Th17 Differentiation Qing Ma, Dan Li, Roza Nurieva, Rebecca.

Advertisements

Host-Derived CD8+ Dendritic Cells Protect Against Acute Graft-versus-Host Disease after Experimental Allogeneic Bone Marrow Transplantation Michael Weber,

High-Risk Acute Lymphoblastic Leukemia Cells with bcr-abl and Ink4a/Arf Mutations Retain Susceptibility to Alloreactive T Cells Faith M. Young, Andrew.

Depletion of Naïve Lymphocytes with Fas Ligand Ex Vivo Prevents Graft-versus-Host Disease without Impairing T Cell Support of Engraftment or Graft-versus-Tumor.

Secondary Lymphoid Organs Contribute to, but Are Not Required for the Induction of Graft-versus-Host Responses following Allogeneic Bone Marrow Transplantation:

Expression of Chemokines in GVHD Target Organs Is Influenced by Conditioning and Genetic Factors and Amplified by GVHR Markus Y. Mapara, Corinna Leng,

Influence of Donor Microbiota on the Severity of Experimental Graft-versus-Host- Disease Isao Tawara, Chen Liu, Hiroya Tamaki, Tomomi Toubai, Yaping Sun,

Host-Derived Interleukin-18 Differentially Impacts Regulatory and Conventional T Cell Expansion During Acute Graft-Versus-Host Disease Robert Zeiser,

Extracorporeal Photopheresis Attenuates Murine Graft-versus-Host Disease via Bone Marrow–Derived Interleukin-10 and Preserves Responses to Dendritic Cell.

IL-2–Targeted Therapy Ameliorates the Severity of Graft-versus-Host Disease: Ex Vivo Selective Depletion of Host-Reactive T Cells and In Vivo Therapy

A CD8 DE loop peptide analog prevents graft-versus-host disease in a multiple minor histocompatibility antigen-mismatched bone marrow transplantation.

In Stem Cell Transplantation by Limiting the Morbidity of Graft-versus-Host Disease Tolerance to Myeloablative Conditioning is Improved Nicolas Novitzky,

Identification of Stem Cell Transcriptional Programs Normally Expressed in Embryonic and Neural Stem Cells in Alloreactive CD8+ T Cells Mediating Graft-versus-Host.

Differential Effects of Gut-Homing Molecules CC Chemokine Receptor 9 and Integrin-β7 during Acute Graft-versus-Host Disease of the Liver Alina Schreder,

Induction of Immunity to Neuroblastoma Early after Syngeneic Hematopoietic Stem Cell Transplantation Using a Novel Mouse Tumor Vaccine Weiqing Jing,

Complete allogeneic hematopoietic chimerism achieved by a combined strategy of in utero hematopoietic stem cell transplantation and postnatal donor lymphocyte.

Apoptotic Donor Leukocytes Limit Mixed-Chimerism Induced by CD40-CD154 Blockade in Allogeneic Bone Marrow Transplantation Jian-ming Li, John Gorechlad,

Induction of heme oxygenase-1 before conditioning results in improved survival and reduced graft-versus-host disease after experimental allogeneic bone.

Preventive Azithromycin Treatment Reduces Noninfectious Lung Injury and Acute Graft- versus-Host Disease in a Murine Model of Allogeneic Hematopoietic.

T-Cell Receptor Vα Usage by Effector CD4+Vβ11+ T Cells Mediating Graft-versus-Host Disease Directed to Minor Histocompatibility Antigens Christine G.

LBH589 Enhances T Cell Activation In Vivo and Accelerates Graft-versus-Host Disease in Mice Dapeng Wang, Cristina Iclozan, Chen Liu, Changqing Xia, Claudio.

IL-12hi Rapamycin-Conditioned Dendritic Cells Mediate IFN-γ–Dependent Apoptosis of Alloreactive CD4+ T Cells In Vitro and Reduce Lethal Graft-Versus-Host.

A Role for TNF Receptor Type II in Leukocyte Infiltration into the Lung during Experimental Idiopathic Pneumonia Syndrome Gerhard C. Hildebrandt, Krystyna.

PreImplantation Factor Reduces Graft-versus-Host Disease by Regulating Immune Response and Lowering Oxidative Stress (Murine Model) Yehudith Azar, Reut.

Sympathectomy Protects Denervated Skin from Graft-Versus-Host Disease

IL-17 Gene Ablation Does Not Impact Treg-Mediated Suppression of Graft-Versus-Host Disease after Bone Marrow Transplantation Lucrezia Colonna, Mareike.

Successful Treatment of Severe Acute Intestinal Graft-versus-Host Resistant to Systemic and Topical Steroids with Alemtuzumab Marc Schnitzler, Jens Hasskarl,

The Synthetic Triterpenoid, CDDO, Suppresses Alloreactive T Cell Responses and Reduces Murine Early Acute Graft-versus-Host Disease Mortality Kai Sun,

Pharmacologic Expansion of Donor-Derived, Naturally Occurring CD4+Foxp3+ Regulatory T Cells Reduces Acute Graft-versus-Host Disease Lethality Without.

The Triterpenoid CDDO-Me Delays Murine Acute Graft-versus-Host Disease with the Preservation of Graft-versus-Tumor Effects after Allogeneic Bone Marrow.

FTY720 Markedly Increases Alloengraftment but Does Not Eliminate Host Anti-Donor T Cells that Cause Graft Rejection on Its Withdrawal Patricia A. Taylor,

Inhibition of Cathepsin S Reduces Allogeneic T Cell Priming but Not Graft-versus-Host Disease Against Minor Histocompatibility Antigens Hisaki Fujii,

Sequential Expression of Adhesion and Costimulatory Molecules in Graft-versus-Host Disease Target Organs after Murine Bone Marrow Transplantation across.

Activated Allogeneic NK Cells as Suppressors of Alloreactive Responses

Xinchun Chen, Yi Zeng, Gang Li, Nicolas Larmonier, Michael W

TIM-1 Blockade of the Donor Graft Provides Protection Against Lethal Gvhd Bettina P. Iliopoulou, PhD, Katie Hsu, MS, Antonio Pierini, MD, Gordon J. Freeman,

Blocking Activator Protein 1 Activity in Donor Cells Reduces Severity of Acute Graft- Versus-Host Disease through Reciprocal Regulation of IL-17–Producing.

Essential Role of Interleukin-12/23p40 in the Development of Graft-versus-Host Disease in Mice Yongxia Wu, David Bastian, Steven Schutt, Hung Nguyen,

Hydrodynamic Delivery of Human IL-15 cDNA Increases Murine Natural Killer Cell Recovery after Syngeneic Bone Marrow Transplantation Isabel Barao, Maite.

T helper17 Cells Are Sufficient But Not Necessary to Induce Acute Graft-Versus-Host Disease Cristina Iclozan, Yu Yu, Chen Liu, Yaming Liang, Tangsheng.

Murine Bone Marrow Stromal Progenitor Cells Elicit an In Vivo Cellular and Humoral Alloimmune Response Andrea T. Badillo, Kirstin J. Beggs, Elisabeth.

T Cell and B Cell Immunity can be Reconstituted with Mismatched Hematopoietic Stem Cell Transplantation Without Alkylator Therapy in Artemis-Deficient.

The Triterpenoid CDDO-Me Delays Murine Acute Graft-versus-Host Disease with the Preservation of Graft-versus-Tumor Effects after Allogeneic Bone Marrow.

A Radio-Resistant Perforin-Expressing Lymphoid Population Controls Allogeneic T Cell Engraftment, Activation, and Onset of Graft-versus-Host Disease in.

Atul Sathe, Sterling B. Ortega, Dorothy I. Mundy, Robert H

Dynamic Change and Impact of Myeloid-Derived Suppressor Cells in Allogeneic Bone Marrow Transplantation in Mice Dapeng Wang, Yu Yu, Kelley Haarberg,

Mammalian Target of Rapamycin Inhibitors Permit Regulatory T Cell Reconstitution and Inhibit Experimental Chronic Graft-versus-Host Disease Haruko Sugiyama,

A CD4 Domain 1 CC′ Loop Peptide Analogue Enhances Engraftment in a Murine Model of Bone Marrow Transplantation with Sublethal Conditioning Gabor Varadi,

Tracking ex vivo-expanded CD4+CD25+ and CD8+CD25+ regulatory T cells after infusion to prevent donor lymphocyte infusion-induced lethal acute graft-versus-host.

In Situ Activation and Expansion of Host Tregs: A New Approach to Enhance Donor Chimerism and Stable Engraftment in Major Histocompatibility Complex-Matched.

Sandra Miklos, Gunnar Mueller, Yayi Chang, Thomas E. O

Treatment with GM-CSF Secreting Myeloid Leukemia Cell Vaccine Prior to Autologous- BMT Improves the Survival of Leukemia-Challenged Mice Jenny Zilberberg,

Recipient B Cells Are Not Required for Graft-Versus-Host Disease Induction Catherine Matte-Martone, Xiajian Wang, Britt Anderson, Dhanpat Jain, Anthony.

Interleukin 17 Is Not Required for Autoimmune-Mediated Pathologic Damage during Chronic Graft-versus-Host Disease Xiao Chen, Rupali Das, Richard Komorowski,

Eva Guinan, Leo Luzmik, Rupert Handgretinger, Ann Woolfrey

CD25 expression distinguishes functionally distinct alloreactive CD4+ CD134+ (OX40+) T-cell subsets in acute graft-versus-host disease Philip R Streeter,

Donor antigen-presenting cells regulate T-cell expansion and antitumor activity after allogeneic bone marrow transplantation Jian-Ming Li, Edmund K.

Post-hematopoietic cell transplantation control of graft-versus-host disease by donor CD4+25+ T cells to allow an effective graft-versus-leukemia response

Brile Chung, Eric Dudl, Akira Toyama, Lora Barsky, Kenneth I. Weinberg

What is quality in a transplant program?

Post-Transplantation Cyclophosphamide and Ixazomib Combination Rescues Mice Subjected to Experimental Graft-versus-Host Disease and Is Superior to Either.

T-Cell Receptor Vα Spectratype Analysis of a CD4-Mediated T-Cell Response against Minor Histocompatibility Antigens Involved in Severe Graft-versus-Host.

Heterogeneity in Studies of Mesenchymal Stromal Cells to Treat or Prevent Graft- versus-Host Disease: A Scoping Review of the Evidence Mina Rizk, Madeline.

Specific donor Vβ-associated CD4+ T-cell responses correlate with severe acute graft- versus-host disease directed to multiple minor histocompatibility.

Volume 62, Issue 1, Pages (July 2002)

Repifermin (keratinocyte growth factor-2) reduces the severity of graft-versus-host disease while preserving a graft-versus-leukemia effect Shawn G Clouthier,

All Hematopoietic Stem Cells Engraft in Submyeloablatively Irradiated Mice Katarina Forgacova, Filipp Savvulidi, Ludek Sefc, Jana Linhartova, Emanuel.

Selective elimination of alloreactive donor T cells attenuates graft-versus-host disease and enhances T-cell reconstitution Maria Gendelman, Maryam Yassai,

Induction of Lethal Graft-versus-Host Disease by Anti-CD137 Monoclonal Antibody in Mice Prone to Chronic Graft-versus-Host Disease Wonyoung Kim, Juyang.

Roles of CD28, CTLA4, and Inducible Costimulator in Acute Graft-versus-Host Disease in Mice Jun Li, Kenrick Semple, Woong-Kyung Suh, Chen Liu, Fangping.

Presentation transcript:

Treatment with a Rho Kinase Inhibitor Improves Survival from Graft-Versus-Host Disease in Mice after MHC-Haploidentical Hematopoietic Cell Transplantation Sujatha Iyengar, Caixin Zhan, Jordan Lu, Robert Korngold, David H. Schwartz Biology of Blood and Marrow Transplantation Volume 20, Issue 8, Pages 1104-1111 (August 2014) DOI: 10.1016/j.bbmt.2014.04.029 Copyright © 2014 American Society for Blood and Marrow Transplantation Terms and Conditions

Figure 1 Fasudil decreases mortality from GVHD. Fasudil administered i.p. for 10 days and in drinking water for the duration of the experiment starting 1 day before lethal irradiation and transfer of ATBM + donor T cells significantly increased 90-day survival from 25% to 73% (P < .0001). Irradiated mice not receiving donor cells showed different early survival rates, with all deaths occurring within a relatively narrow window of 12 to 16 days. Data were pooled from 3 separate replicate experiments involving total sample sizes of 10 to 26 for the different groups, as indicated. Biology of Blood and Marrow Transplantation 2014 20, 1104-1111DOI: (10.1016/j.bbmt.2014.04.029) Copyright © 2014 American Society for Blood and Marrow Transplantation Terms and Conditions

Figure 2 Fasudil does not fully prevent weight loss during acute GVHD. Despite impressive reduction in mortality, mice receiving fasudil along with ATBM + donor T cells were not spared significant weight loss, comparable with untreated ATBM + T recipients, during the first month post-transplantation. In the first week, these groups lost 2 to 3 times as much weight as did ATBM only recipients or as irradiated mice receiving no donor cells. Fasudil-treated mice surviving the first month of ATBM + T cell transplantation, as well as far fewer untreated surviving mice, gradually gained back more of their lost weight than the fewer surviving untreated mice (P = .001), but never caught up with the ATBM-only group (P < .0001). Biology of Blood and Marrow Transplantation 2014 20, 1104-1111DOI: (10.1016/j.bbmt.2014.04.029) Copyright © 2014 American Society for Blood and Marrow Transplantation Terms and Conditions

Figure 3 Long-term fasudil-treated and untreated survivors of GVHD have minimal inflammation of sampled tissues. Most small bowel sections from fasudil-treated animals showed normal architecture of crypts and villi, without evidence of inflammation (A). In 3 of 5 animals, scattered areas of lamina propria and basilar crypt inflammation were seen (dashed white lines), with no disruption of the crypt or villous architecture (B). No inflammation was observed in multiple samples taken from 3 untreated surviving animals (not shown). Biology of Blood and Marrow Transplantation 2014 20, 1104-1111DOI: (10.1016/j.bbmt.2014.04.029) Copyright © 2014 American Society for Blood and Marrow Transplantation Terms and Conditions

Figure 4 CFSE dilution peak determination of spleen cell alloreactivity in 1-way mixed lymphocyte reactions (responder versus irradiated stimulator). Pooled splenocytes from mice 98 days after receiving C3H donor anti-thy-1 treated bone marrow only (ATBM) made some proliferative response to host B6C3F1 cells (A). Roughly 11% of cells divided once, and 17% divided more than once, which is expected as a consequence of normal responses to self-restricted foreign environmental antigens. More cells (40% versus 17%, P < .001) responded with 2 or more cell divisions when third-party BALB/c cells were used as stimulators (B). By contrast, spleen cells from mice receiving mature donor T cells along with ATBM made a strong response to host B6C3F1 cell stimulation, with ∼7% dividing once and ∼31% more than once (C), not significantly different from their response (8% and 32%, respectively) to BALB/c (D), but significantly greater than (A) ATBM anti-F1 responses (P < .001). Mice receiving fasudil, along with donor T cells and ATBM (E), also made a stronger alloresponse to B6C3F1 host cells than mice receiving only ATBM (A), with 20% dividing once and 21% dividing more than once. Although these proportions both differ significantly (P < .001) from the respective proportions of cells from the untreated mice (C), they are still greater in both cases than the corresponding peaks in ATBM-only spleen cultures (P < .001) and, compared with (C), also have a population of cells undergoing additional rounds of alloreactive division (lowest signal intensity peak). Fasudil-treated mice also retained strong anti-BALB/c MHC responses (F), with a peak profile roughly similar in distribution to (E). Data are representative of 2 replicate experiments and 4 culture time points. Biology of Blood and Marrow Transplantation 2014 20, 1104-1111DOI: (10.1016/j.bbmt.2014.04.029) Copyright © 2014 American Society for Blood and Marrow Transplantation Terms and Conditions